




Searching News Database: Pompe disease
HSMN NewsFeed - 19 Dec 2019
Protalix BioTherapeutics Adds Two Accomplished Biopharmaceutical Executives to its Board of Directors
Protalix BioTherapeutics Adds Two Accomplished Biopharmaceutical Executives to its Board of Directors
HSMN NewsFeed - 13 Dec 2017
Audentes Therapeutics Appoints Mark A. Goldberg, M.D. to its Board of Directors
Audentes Therapeutics Appoints Mark A. Goldberg, M.D. to its Board of Directors
HSMN NewsFeed - 3 Mar 2017
Valerion Therapeutics Demonstrates a New Mechanism for Treating Pompe Disease
Valerion Therapeutics Demonstrates a New Mechanism for Treating Pompe Disease
HSMN NewsFeed - 2 Oct 2015
Amicus Therapeutics Provides U.S. Regulatory Update for Migalastat Monotherapy
Amicus Therapeutics Provides U.S. Regulatory Update for Migalastat Monotherapy
HSMN NewsFeed - 20 Jul 2015
BioMarin Provides Program Update for Talazoparib in Metastatic Breast Cancer
BioMarin Provides Program Update for Talazoparib in Metastatic Breast Cancer
HSMN NewsFeed - 27 Apr 2015
Amicus Therapeutics Appoints David Allsop as Senior Vice President, International
Amicus Therapeutics Appoints David Allsop as Senior Vice President, International
HSMN NewsFeed - 20 Aug 2014
Amicus Therapeutics Announces Positive Phase 3 Data From Fabry Monotherapy Study 012
Amicus Therapeutics Announces Positive Phase 3 Data From Fabry Monotherapy Study 012
HSMN NewsFeed - 10 Sep 2013
Amicus Therapeutics Enters Collaboration With Biogen Idec for Parkinson's Disease
Amicus Therapeutics Enters Collaboration With Biogen Idec for Parkinson's Disease
HSMN NewsFeed - 3 Sep 2013
BioMarin Appoints Richard Ranieri as Senior Vice President, Human Resources and Corporate Affairs
BioMarin Appoints Richard Ranieri as Senior Vice President, Human Resources and Corporate Affairs
HSMN NewsFeed - 29 Jun 2011
Amicus Therapeutics Announces John F. Crowley to Return as Chairman and Chief Executive Officer
Amicus Therapeutics Announces John F. Crowley to Return as Chairman and Chief Executive Officer
HSMN NewsFeed - 13 Dec 2007
Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
HSMN NewsFeed - 5 Mar 2007
Amicus Therapeutics Announces Return of John F. Crowley as President and Chief Executive Officer
Amicus Therapeutics Announces Return of John F. Crowley as President and Chief Executive Officer
HSMN NewsFeed - 23 Jan 2007
Amicus Therapeutics Receives Grant From Michael J. Fox Foundation for Parkinson's Research
Amicus Therapeutics Receives Grant From Michael J. Fox Foundation for Parkinson's Research
HSMN NewsFeed - 14 Sep 2006
Amicus Therapeutics Raises $60 Million Series D Financing; Company Also Makes Two Key Executive Appointments
Amicus Therapeutics Raises $60 Million Series D Financing; Company Also Makes Two Key Executive Appointments
Additional items found! 4

Members Archive contains
4 additional stories matching:
Pompe disease
(Password required)
Pompe disease
(Password required)